Novartis AG recently unveiled findings from the VAYHIT2 Phase 3 trial of ianalumab alongside eltrombopag in patients with primary immune thrombocytopenia (ITP) who had previously undergone corticosteroid treatment. The VAYHIT2 trial, as disclosed in August, showed positive outcomes. The combination of ianalumab at a dosage of 9 mg/kg and eltrombopag increased ITP disease management by 45%, as measured by the primary endpoint of time to treatment failure (TTF), which gauges the duration patients maintain safe platelet levels throughout and after treatment. The median time to treatment effectiveness extended significantly.